Safety of ribavirin in adolescent thalassemic patients with chronic hepatitis C virus infection

Uslu, Nuray; Baysoy, Gökhan; Demır, Hülya; Saltık-Temizel, İnci Nur; Yüce, Aysel

doi:10.1016/j.jcv.2010.02.011

Cited by 2 publications

(2 citation statements)

References 21 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The study identified 1483 references through the electronic searches on MEDLINE, CENTRAL, EMBASE, SCOPUS, ISI, Google Scholar, clinicaltrials.gov, controlledtrials.gov, centerwatch.com and manual searches; after reading the abstracts and titles 1427 clearly irrelevant to topic and duplicate references were excluded ( Figure 1 ). From 56 potentially relevant studies after reading full texts, eight case-reports and case series were excluded ( 18 - 25 ), one study was excluded because it was conducted on patients after bone marrow transplantation ( 26 ), another study was excluded for co-infection of participants with hepatitis B ( 27 ), two reviews were excluded ( 28 , 29 ), seven studies were excluded because of low sample size 2 - 8 patients ( 30 - 36 ), one study was excluded due to lack of methodological report ( 37 ), a study was excluded because it reported just EVR ( 38 ), four studies were excluded because they were duplicate publications of the same patients data as seminar proceedings ( 39 - 42 ), 25 studies were excluded since they were prospective, without a control group ( 7 , 12 , 43 - 65 ), three non-randomized controlled trials were also excluded ( 66 - 68 ) and finally three randomized controlled trials were included in the meta-analysis ( 11 , 69 , 70 ).…”

Section: Resultsmentioning

confidence: 99%

Safety and Efficacy of Adding Ribavirin to Interferon or Peginterferon in Treatment of Hepatitis C Infection in Patients With Thalassemia: A Systematic Review on Randomized Controlled Trials

et al. 2016

View full text Add to dashboard Cite

ContextHepatitis C virus (HCV) infection is a major cause of liver-morbidity and mortality among patients with thalassemia. Peginterferon plus ribavirin is currently the recommended therapy for hepatitis C infection in patients do not have thalassemia, but using ribavirin in patients with thalassemia is restricted due to its hemolytic effect. To evaluate the efficacy and safety of adding ribavirin to peginterferon or interferon, authors performed a systematic review on the available literatures.Evidence AcquisitionTrials were identified through electronic database, manual searches of journals and bibliographies and approaching authors of trials. Randomized trials that enrolled patients with a diagnosis of thalassemia and chronic hepatitis C infection treated with interferon or peginterferon with or without ribavirin were included. Two investigators independently evaluated the trials for inclusion criteria, risk of bias and data extraction. The primary outcomes were sustained virological response (SVR), liver-related morbidity, mortality and adverse events. The odds ratios from each trial were calculated individually and in the subgroup analysis of trials. Data were analyzed with fixed-effect model.ResultsThree randomized clinical trials with 92 patients were included. All three trials had unclear risk of bias. Compared with peginterferon monotherapy, adding ribavirin to peginterferon had significant beneficial effect on sustained virological response (OR = 3.44, 95% CI: 1.18 - 10.06). There was no significant difference between combination therapy and monotherapy in the end of treatment achievement response. Other than about 30% increase in blood transfusion due to anemia that returned to normal level 2 - 3 months after treatment, there was no significant increase in side effects followed by adding ribavirin to pegylated interferon (Peg-IFN). Data were insufficient to determine the impact of genotype, viral load and age on the response to treatment.ConclusionsCompared with monotherapy, adding ribavirin to treatment is more effective in removing hepatitis C virus from the bloodstream in patients with thalassemia, it is also more effective in reducing the relapse rate after treatment. Except the increase in blood transfusion, there was no significant increase in side effects followed by adding ribavirin.

show abstract

Section: Resultsmentioning

confidence: 99%

Safety and Efficacy of Adding Ribavirin to Interferon or Peginterferon in Treatment of Hepatitis C Infection in Patients With Thalassemia: A Systematic Review on Randomized Controlled Trials

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Haftada 3 kez 3 MÜ IFN verilen 28 thalassemia major (b-talasemi) hastasının 8'inde KVY elde edilmiş, 20 hasta yanıtsız bulunmuştur (200). Bir çalışmada, 48 haftalık PegIFN ve 800 mg RBV tedavisi verilen adolesan çağdaki iki talasemili hastada, tedavi sırasında ek transfüz-yon gereksinimi olmadığı ve nötropeni gelişmediği; dördün-cü yıldaki HCV RNA'nın da negatif olduğu (201); bir başka çalışmada ise PegIFN ve RBV kombinasyonunun transfüzyon gereksinimini artırdığı bildirilmiştir (202). KHC tedavisi verilen b-talasemili 12 hastadan 3'ü çok erken olarak, biri persistan ateş nedeniyle 8. haftada, 2'si de hemolitik anemi nedeniyle çalışmayı bırakmış ve tedaviyi tamamlayan 7 hastadan 5'inde KVY elde edilmiştir (203).…”

Section: Hemoglobinopati Ve Kronik Hepatit Cunclassified

Management of Chronic Hepatitis in Special Hosts and Special Situations: A Consensus Report of the Study Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases

Mıstık¹,

Aydın²,

Aksoy³

et al. 2015

Klimik Dergisi

View full text Add to dashboard Cite

ÖzetTürk Klinik Mikrobiyoloji ve İnfeksiyon Hastalıkları Derneği Viral Hepatit Çalışma Grubu, özel konaklarda ve özel durumlarda kronik hepatit yönetimine ilişkin bir uzlaşı raporu hazırlamak üzere bir toplantı düzenlemiştir. Raporda konuyla ilgili literatür ve uluslararası kılavuzlar, hepatit B virusu (HBV) için sırasıyla kompanse ve dekompanse sirozlu hastalarda kronik hepatit B (KHB) tedavisi, karaciğer nakli sonrası HBV infeksiyonunun nüks etmesinden korunma ve nüks gelişen hastalarda tedavi, fülminan hepatit B tedavisi, hemodiyaliz hastalarında KHB teda- AbstractStudy Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases convened a meeting to develop a consensus report on management of chronic hepatitis in special hosts and special situations. Relevant literature and international guidelines were reviewed, and recommendations agreed are presented at the end of each section such as therapy of chronic hepatitis B (CHB) in patients with compensated and decompensated cirrhosis, prevention and therapy of recurrent hepatitis B after liver transplantation, management of fulminant

show abstract

Safety of ribavirin in adolescent thalassemic patients with chronic hepatitis C virus infection

Cited by 2 publications

References 21 publications

Safety and Efficacy of Adding Ribavirin to Interferon or Peginterferon in Treatment of Hepatitis C Infection in Patients With Thalassemia: A Systematic Review on Randomized Controlled Trials

Safety and Efficacy of Adding Ribavirin to Interferon or Peginterferon in Treatment of Hepatitis C Infection in Patients With Thalassemia: A Systematic Review on Randomized Controlled Trials

Management of Chronic Hepatitis in Special Hosts and Special Situations: A Consensus Report of the Study Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases

Contact Info

Product

Resources

About